ES3010130T3 - Engrailed for treatment of amyotrophic lateral sclerosis - Google Patents
Engrailed for treatment of amyotrophic lateral sclerosis Download PDFInfo
- Publication number
- ES3010130T3 ES3010130T3 ES21189549T ES21189549T ES3010130T3 ES 3010130 T3 ES3010130 T3 ES 3010130T3 ES 21189549 T ES21189549 T ES 21189549T ES 21189549 T ES21189549 T ES 21189549T ES 3010130 T3 ES3010130 T3 ES 3010130T3
- Authority
- ES
- Spain
- Prior art keywords
- neurons
- engrailed
- mice
- ohda
- snpc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306482 | 2015-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3010130T3 true ES3010130T3 (en) | 2025-04-01 |
Family
ID=54207439
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21189549T Active ES3010130T3 (en) | 2015-09-23 | 2016-09-23 | Engrailed for treatment of amyotrophic lateral sclerosis |
| ES16777596T Active ES2895154T3 (es) | 2015-09-23 | 2016-09-23 | Engrailed para su uso en el tratamiento de daños en el ADN en un paciente que padece la enfermedad de Parkinson |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16777596T Active ES2895154T3 (es) | 2015-09-23 | 2016-09-23 | Engrailed para su uso en el tratamiento de daños en el ADN en un paciente que padece la enfermedad de Parkinson |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20190247461A1 (enExample) |
| EP (2) | EP3960195B1 (enExample) |
| JP (1) | JP6860575B2 (enExample) |
| CN (1) | CN108289929A (enExample) |
| ES (2) | ES3010130T3 (enExample) |
| PL (2) | PL3352777T3 (enExample) |
| WO (1) | WO2017071889A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026503094A (ja) | 2023-01-13 | 2026-01-27 | ブレインエバー | 安定化エングレイルドタンパク質水性組成物 |
| EP4781999A1 (en) * | 2025-01-24 | 2026-07-29 | Brainever | Engrailed protein for use in the treatment of tdp-43 proteinopathies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2662698A1 (fr) * | 1990-06-05 | 1991-12-06 | Centre Nat Rech Scient | Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite. |
| FR2855178B1 (fr) * | 2003-05-20 | 2005-08-05 | Centre Nat Rech Scient | Peptides modulateurs de l'activite du facteur de transcription engrailed |
| FR2897780B1 (fr) | 2006-02-28 | 2008-05-23 | Centre Nat Rech Scient | Utilisation de la proteine a homeodomaine engrailed comme anxiolytique |
| GB0625321D0 (en) * | 2006-12-19 | 2007-01-24 | Univ Surrey | Cancer biomarker |
| FR2926023B1 (fr) | 2008-01-09 | 2010-02-26 | Centre Nat Rech Scient | Utilisation d'une homoproteine de la famille bicoid pour le traitement du glaucome. |
| JP2012532621A (ja) * | 2009-07-13 | 2012-12-20 | ザ ユニバーシティ オブ サリー | 治療ペプチド、ポリペプチド及び核酸配列 |
| WO2013128239A1 (en) | 2012-02-29 | 2013-09-06 | Centre National De La Recherche Scientifique | Use of engrailed for increasing dopamine synthesis by dopaminergic neurons |
-
2016
- 2016-09-23 WO PCT/EP2016/072675 patent/WO2017071889A1/en not_active Ceased
- 2016-09-23 EP EP21189549.5A patent/EP3960195B1/en active Active
- 2016-09-23 CN CN201680059070.1A patent/CN108289929A/zh active Pending
- 2016-09-23 ES ES21189549T patent/ES3010130T3/es active Active
- 2016-09-23 PL PL16777596T patent/PL3352777T3/pl unknown
- 2016-09-23 JP JP2018534025A patent/JP6860575B2/ja active Active
- 2016-09-23 EP EP16777596.4A patent/EP3352777B1/en active Active
- 2016-09-23 US US15/761,702 patent/US20190247461A1/en not_active Abandoned
- 2016-09-23 ES ES16777596T patent/ES2895154T3/es active Active
- 2016-09-23 PL PL21189549.5T patent/PL3960195T3/pl unknown
-
2021
- 2021-06-16 US US17/349,746 patent/US20210379144A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2999209A1 (en) | 2017-05-04 |
| EP3352777B1 (en) | 2021-09-15 |
| PL3960195T3 (pl) | 2025-06-09 |
| EP3960195B1 (en) | 2025-01-08 |
| US20210379144A1 (en) | 2021-12-09 |
| US20190247461A1 (en) | 2019-08-15 |
| JP6860575B2 (ja) | 2021-04-14 |
| CN108289929A (zh) | 2018-07-17 |
| PL3352777T3 (pl) | 2022-02-07 |
| WO2017071889A1 (en) | 2017-05-04 |
| ES2895154T3 (es) | 2022-02-17 |
| JP2018536697A (ja) | 2018-12-13 |
| EP3352777A1 (en) | 2018-08-01 |
| EP3960195A1 (en) | 2022-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2696598T3 (es) | Compuestos de balanol para su uso en el tratamiento de dolor | |
| Wu et al. | Protection of dexmedetomidine against ischemia/reperfusion‐induced apoptotic insults to neuronal cells occurs via an intrinsic mitochondria‐dependent pathway | |
| Ong et al. | Mitochondrial dynamics as a therapeutic target for treating cardiac diseases | |
| Wang et al. | Sestrin2 overexpression attenuates focal cerebral ischemic injury in rat by increasing Nrf2/HO-1 pathway-mediated angiogenesis | |
| Xie et al. | Intranasal administration of recombinant Netrin-1 attenuates neuronal apoptosis by activating DCC/APPL-1/AKT signaling pathway after subarachnoid hemorrhage in rats | |
| Sun et al. | p27 protein protects metabolically stressed cardiomyocytes from apoptosis by promoting autophagy | |
| Wu et al. | Recombinant adiponectin peptide promotes neuronal survival after intracerebral haemorrhage by suppressing mitochondrial and ATF4‐CHOP apoptosis pathways in diabetic mice via Smad3 signalling inhibition | |
| ES2992748T3 (en) | Antagonists of cav2.3 r-type calcium channels for the treatment of neurodegenerative diseases | |
| Li et al. | RP105 protects against myocardial ischemia–reperfusion injury via suppressing TLR4 signaling pathways in rat model | |
| Feng et al. | Trilobatin attenuates cerebral ischaemia/reperfusion‐induced blood–brain barrier dysfunction by targeting matrix metalloproteinase 9: The legend of a food additive | |
| Yu et al. | Neuroprotective effect of nicorandil through inhibition of apoptosis by the PI3K/Akt1 pathway in a mouse model of deep hypothermic low flow | |
| US20130197069A1 (en) | Methods for treating stress induced emotional disorders | |
| US20210379144A1 (en) | Homeoproteins for use in the treatment of neurodegenerative disorders | |
| Song et al. | Fasudil, a Rho-associated protein kinase inhibitor, attenuates retinal ischemia and reperfusion injury in rats | |
| EP2200630A1 (en) | Treatment of cardiovascular disorders using the cell differentiation signaling protein nell1 | |
| WO2014087240A2 (en) | Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis | |
| Pavone et al. | The Rac GTPase-activating bacterial protein toxin CNF1 induces analgesia up-regulating μ-opioid receptors | |
| Lu et al. | Remifentanil alleviates hypoxic-ischemic brain damage-induced cognitive impairment via BACH1 | |
| CA2999209C (en) | Homeoproteins for use in the treatment of neurodegenerative disorders | |
| US11083708B2 (en) | Pharmacological restoration of epithelial or endothelial barrier integrity by agents blocking EPAC/RAP1 signaling | |
| KR20150096687A (ko) | 교모세포종 치료에 있어서의 항분비 인자(af)의 용도 | |
| US20100189802A1 (en) | Method for treatment of vascular hyperpermeability | |
| ES2396468T3 (es) | Composiciones para uso en el tratamiento del síndrome mielodisplástico | |
| Chen et al. | Targeting neuronal HK2 alleviates glutamate neurotoxicity and MCAO-induced ischemic brain injury | |
| JP2019510015A (ja) | Ｂｃｌ−２ ｌ１０／ｉｐ３受容体の相互作用の阻害剤 |